AbbVie (ABBV) will invest $195 million to expand its North Chicago, Illinois manufacturing facility, boosting domestic production of active pharmaceutical ingredients or APIs.
This move is part of the company's broader plan to invest over $10 billion in the U.S. to advance innovation and enhance manufacturing capabilities. The new facility will increase AbbVie's chemical synthesis capacity to produce current and future neuroscience, immunology, and oncology treatments.
Construction starts in fall 2025, with operations expected by 2027. AbbVie's U.S. manufacturing network already supports more than 6,000 jobs across 11 sites, alongside thousands more at suppliers. The investment also reinforces AbbVie's long-standing presence in Illinois, where over 11,000 employees are based.
AbbVie CEO Robert A. Michael stated that the company plans to expand production of APIs, drug products, peptides, and medical devices in the U.S. over the next decade to drive future medical breakthroughs and maintain U.S. leadership in pharmaceutical innovation.
Illinois Governor JB Pritzker highlighted that AbbVie's expansion reflects the state's strong workforce, infrastructure, research institutions, and connectivity, strengthening Illinois' biomanufacturing sector while creating jobs and developing next-generation medicines.
Tuesday, ABBV closed unchanged at $198.64 and is trading after hours at $199, up 0.18% on the NYSE.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.